Evaluation of the Benefits of Bilateral Fitting in BAHS Users

Sponsor
Oticon Medical (Industry)
Overall Status
Completed
CT.gov ID
NCT04006132
Collaborator
(none)
26
1
1
6.2
4.2

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the benefit of bilateral implantation with bone-anchored hearing systems (BAHS), in terms of sound localization abilities, as well as auditory working memory. The hypothesis is that the use of two BAHS (bilateral condition) will not only improve localization abilities, but it will also increase the ability to retain words in working memory, compared to performance with only one BAHS (unilateral condition).

Condition or Disease Intervention/Treatment Phase
  • Device: Fitting of Ponto 3 SuperPower
N/A

Detailed Description

The patients included in this study are adult patients with a bilateral conductive or mixed hearing loss, that are already bilaterally implanted with two percutaneous bone-anchored devices (BAHS). The study consists of two visits. At visit 1, the patients are fitted unilaterally and bilaterally with the investigational device (Ponto 3 SuperPower). After fitting, the patients perform a test of spatial resolution (minimum audible angle, visit 1) and an auditory working memory test (visit 2). These two outcome measures are conducted in the laboratory using the Ponto 3 SuperPower unilaterally and bilaterally. Additionally, the patients fill in a questionnaire (SSQ12) to report perceived performance in their everyday life with their own devices. This is a post market study and all products used are CE marked and used in clinical practice worldwide.

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
The participants are blinded to the tested condition (unilateral vs bilateral)
Primary Purpose:
Basic Science
Official Title:
Evaluation of the Benefits of Bilateral Fitting in Bone-anchored Hearing System Users
Actual Study Start Date :
Jul 4, 2019
Actual Primary Completion Date :
Jan 7, 2020
Actual Study Completion Date :
Jan 10, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ponto 3 SuperPower sound processor

All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.

Device: Fitting of Ponto 3 SuperPower
Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.

Outcome Measures

Primary Outcome Measures

  1. Minimum Audible Angle test [4 months]

    Minimum angle at which noise bursts are accurately localized (Right/Left) in the unilateral and bilateral conditions

Secondary Outcome Measures

  1. SWIR test [4 months]

    Percentage of recalled words in the unilateral and bilateral conditions

  2. SSQ12 [4 months]

    Subjective performance as measured by Speech, Spatial and Qualities of Hearing questionnaire (SSQ); 12 items with a scale from 0-10 where 0 represents "Not at all" and 10 represents "Perfect"

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult BAHS users, minimum 18 years and maximum 75 years.

  • Native English speakers.

  • Patients that are already bilaterally implanted.

  • Patients with a bilateral conductive or mixed conductive-sensorineural hearing loss.

  • Experience with bilateral Ponto of at least 6 months.

  • Patients that are using both their sound processors daily.

  • PTA BC (at 0.5, 1, 2, 3 kHz) on both sides lower or equal to 65 dB HL.

  • If the masked BC is available on the patient's journal, the average difference in masked BC (at 0.5, 1, 2, 4 kHz) between L and R ear should be lower than 15 dB.

  • If the masked BC is not available on the patient's journal, the average difference in unmasked BC (at 0.5, 1, 2, 4 kHz) between L and R ear should be lower than 15 dB.

Exclusion Criteria:
  • Not deemed suited by the principal investigator.

  • If the physician assesses that the patient is not fit for trial participation at any stage.

  • Audiogram at 1st visit shows too large masked BC thresholds (PTA BC - at 0.5, 1, 2, 3 kHz - on either side larger than 65 dB HL).

  • Audiogram at 1st visit shows asymmetric masked BC thresholds (average difference in masked BC - at 0.5, 1, 2, 4 kHz - between L and R ear larger or equal to 15 dB).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Audiology Department, Nuffield House, University Hospitals Birmingham Birmingham West Midlands United Kingdom B15 2TH

Sponsors and Collaborators

  • Oticon Medical

Investigators

  • Principal Investigator: William Brassington, University Hospitals Birmingham, United Kingdom

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Oticon Medical
ClinicalTrials.gov Identifier:
NCT04006132
Other Study ID Numbers:
  • C71
First Posted:
Jul 5, 2019
Last Update Posted:
Jan 23, 2020
Last Verified:
Jan 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Oticon Medical
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 23, 2020